NHS pilots to speed up access to new medicines
According to the Department of Health and Social Care, a new set of NHS pilots could help some patients get innovative medicines months earlier than they do now. The pilots are due to begin testing new ideas from September 2026, and the promise is easy to grasp: if a treatment is already shown to work, people should not be left waiting longer than necessary. That sounds simple, but medicines access is rarely simple. A drug can clear scientific and clinical checks and still face delays over price, NHS readiness and local rollout. This announcement is really about that gap between a medicine existing and a patient actually receiving it.
The plan was drawn up in a 10-week 'sprint' by a joint taskforce made up of government, the pharmaceutical industry and NHS representatives, with patient organisations feeding into the work. If you have ever wondered who gets a say in medicines policy, the answer is usually several groups at once, each with different priorities. **What this means for you:** this is not only a science story. It is also a public money story about who pays, how value is judged and whether patients in different places get the same chance of treatment.
One pilot will focus on medicines that have already met safety, quality and clinical standards, including treatments for rare conditions. The aim is to get eligible patients into access programmes sooner instead of waiting for every step of the usual process to finish before the NHS can move. For families affected by rare diseases, that detail matters a great deal. Many rare conditions worsen over time, so a delay of a few months is not a small paperwork issue; it can mean someone becomes too ill to benefit in the same way. Genetic Alliance UK made exactly that point, saying earlier managed access could save lives.
The government is linking these pilots to changes made in April 2026 to NICE's cost-effectiveness threshold. Since that change was announced, NICE says nine additional medicines have already been approved for NHS patients in England and Wales. Those approvals cover serious and life-limiting illnesses, including blood disorders, autoimmune diseases and several cancers. Among them are treatments for brain tumours affecting very young children and advanced stomach cancers where options can be limited. **In plain English:** the threshold is one of the tests NICE uses to decide whether a medicine offers enough benefit for the price the NHS would pay.
NICE says the new arrangements could lead to up to five extra medicines being approved each year compared with the old system. It also points out that it already approves more than 90% of the medicines it assesses, which is a useful reminder that the biggest problem is not always a flat no. Quite often, the harder question is whether an approval turns into real access at a similar speed across the NHS. That is why ministers are talking about fairness as well as speed. James Murray said patients should not have to wait once a medicine is proven to work, but he also framed the policy as a value-for-money issue for taxpayers.
The other pilots show that this is about more than the final price tag on a box of medicine. One will test whether the system should give more weight to wider benefits, such as helping someone return to work. Another would let companies co-invest in screening, testing and the full package of care needed so hospitals can offer a treatment quickly once NICE recommends it. There is also a plan for dedicated regional funding to improve access to priority medicines. That could help with a long-running NHS problem: a treatment may be approved nationally, yet uptake can still vary because local services have different staffing, budgets or practical barriers. **What to watch:** if industry money is involved more directly, the rules will need to stay clear so patient need and public value remain the first test.
This sits inside a much bigger government target. Under the UK-US pharmaceutical arrangement, ministers have committed to doubling spending on innovative medicines from 0.3% to 0.6% of GDP over the next decade. Alongside the patient case, the government is also making an industrial case: pharmaceuticals bring research, manufacturing and commercial jobs, and ministers want the UK to look more attractive to investors. Science Minister Lord Vallance presented the pilots as part of getting the NHS ready for a period of faster medical progress. Richard Torbett of the ABPI welcomed the move as a sign that government and industry are trying to build confidence after earlier rows about how innovative medicines are paid for.
Patient groups were positive, but their support came with a clear warning about delay. Dr Scott Purdon of the Charity Medicines Access Coalition said waiting does not just frustrate people; it can shorten lives and worsen quality of life. That is a helpful check on official language, because it reminds us that behind every pilot scheme are real people waiting for treatment, often while their condition changes. So the headline is hopeful, but the real test comes next. If the pilots starting in September 2026 lead to quicker decisions, smoother rollout and more equal access across the NHS, patients will feel the difference. If they only add another layer of policy language, families will notice that too.